All In Biotech

Investigational drug · Phase 2

LY03020

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Schizophrenia.

Phase 2

Last checked: Nov 19, 2026Latest source record: Feb 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

4

Any phase or sponsor naming "LY03020"

First trial start

2026

Mar 31, 2026

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "LY03020", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Schizophrenia

Approved drugs for the same conditions: Schizophrenia · Psychiatry

Largest trials

Live from ClinicalTrials.gov: studies naming "LY03020" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Schizophrenia

  • KarX-ECBMS-986519, Xanomeline Enteric-coatedPhase 39 trials

    Bristol Myers Squibb · Alzheimer Disease, Alzheimer's Disease, Irritability Associated With Autism Spectrum Disorder

  • SEP-363856UlotarontPhase 37 trials

    Otsuka · Generalized Anxiety Disorder, Schizophrenia, Major Depressive Disorder

  • NBI-1117568Phase 35 trials

    Neurocrine Biosciences · Schizophrenia, Bipolar I Disorder, Mania

  • LB-102Phase 34 trials

    LB Pharmaceuticals Inc. · Schizophrenia, Bipolar I Disorder

  • SPG302TazbentetolPhase 33 trials

    Spinogenix · Alzheimer Disease, Schizophrenia, Amyotrophic Lateral Sclerosis

  • OLZSAM, ALKS 3831Phase 32 trials

    Alkermes, Inc. · Bipolar I Disorder, Schizophrenia

  • B2227Phase 31 trial

    Bostal Drug Delivery Co., Ltd · Schizophrenia

  • ML-007C-MAPhase 24 trials

    MapLight Therapeutics · Psychosis Associated With Alzheimer's Disease, Schizophrenia

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.